Addressing screams for evidence on renoprotection by GLP-1 receptor agonists

Abstract

Although growing evidence supports the benefits of glucagon-like peptide-1 receptor agonists, the renoprotective effects were not fully proven in clinical trials. Now, Xu etal. show that glucagon-like peptide-1 receptor agonists reduce the renal outcome compared with dipeptidyl peptidase-4 inhibitors in a retrospective cohort study of the participants in the Stockholm Creatinine Measurements project undertaken in Stockholm, Sweden. Despite some limitations, the study shows renoprotection by glucagon-like peptide-1 receptor agonists and raises hope about upcoming evidence from prospective clinical trials.